A phase II study of ramucirumab for advanced, pre-treated biliary cancers.

被引：2
|
作者：
Mizrahi, Jonathan
Javle, Milind M.
Xiao, Lianchun
Varadhachary, Gauri R.
Raghav, Kanwal Pratap Singh
Wolff, Robert A.
Shroff, Rachna T.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept GI Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.4081
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4081
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Advanced Gastrointestinal Tumors Ramucirumab: Opportunities for pre-Treated Patients
    不详
    VISCERAL MEDICINE, 2018, 34 (01) : 80 - 80
  • [2] Advanced Gastrointestinal Tumors Ramucirumab: Prognostic Benefits for the pre-treated Patients
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (12)
  • [3] Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy
    Lee, Sunyoung
    Shroff, Rachna T.
    Makawita, Shalini
    Xiao, Lianchun
    De Armas, Anaemy Danner
    Bhosale, Priya
    Reddy, Kavitha
    Shalaby, Ahmed
    Raghav, Kanwal
    Pant, Shubham
    Wolff, Robert A.
    Javle, Milind
    CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2229 - 2236
  • [4] Phase II study of nivolumab and ipilimumab for advanced rare genitourinary cancers.
    McGregor, Bradley Alexander
    Campbell, Matthew T.
    Xie, Wanling
    Farah, Subrina
    Bilen, Mehmet Asim
    Sonpavde, Guru
    Kilbridge, Kerry L.
    Choudhury, Atish Dipankar
    Mortazavi, Amir
    Shah, Amishi Yogesh
    Venkatesan, Aradhana M.
    Bubley, Glenn
    Siefker-Radtke, Arlene O.
    McKay, Rana R.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] FOLFIRI in advanced biliary tract cancers.
    Mizrahi, Jonathan
    Gunchick, Valerie
    Mody, Kabir
    Xiao, Lianchun
    Surapaneni, Phani Keerthi
    Shroff, Rachna T.
    Sahai, Vaibhav
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [6] A phase II study of Gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer
    Friedlander, M
    Millward, MJ
    Bell, D
    Bugat, R
    Harnett, P
    Moreno, JA
    Campbell, L
    Varette, C
    Ripoche, V
    Kayitalire, L
    ANNALS OF ONCOLOGY, 1998, 9 (12) : 1343 - 1345
  • [7] Multi institutional phase II trial of single agent regorafenib in refractory advanced biliary cancers.
    Kim, Richard D.
    Poklepovic, Andrew Stewart
    Nixon, Andrew B.
    Kim, Dae Won
    Soares, Heloisa P.
    Kim, Jongphil
    Zhou, Jun Min
    Tariq, Fatima
    Burgess, Natalie
    Sanoff, Hanna Kelly
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] A phase II study of oxaliplatin (O) and gemcitabine (G) first line chemotherapy in patients with advanced biliary tract cancers.
    Gebbia, N
    Verderame, F
    Di Leo, R
    Santangelo, D
    Cicero, G
    Valerio, MR
    Arcara, C
    Badalamenti, G
    Fulfaro, F
    Carreca, I
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 340S - 340S
  • [9] Phase II study of anlotinib plus sintlimab as second-line treatment for patients with advanced biliary tract cancers.
    Zong Hong
    Zhong Qian
    Zhao Ruihua
    Jin Shuiling
    Zhou Chuang
    Zhang Xiaojian
    Shi Jianxiang
    Qiao Shishi
    Han Jinming
    Jiang Miao
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [10] Randomized, multicenter phase II trial of CAP7.1 in patients with advanced biliary tract cancers.
    Pape, Ulrich-Frank
    Kasper, Stefan
    Sinn, Marianne
    Caca, Karel
    Kuhlmann, Jan
    Keilholz, Ulrich
    Vogel, Arndt
    Utku, Nalan
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345